FDA maintains data insufficiency concerns regarding Replimune skin cancer therapy

FDA staff have reaffirmed that Replimune's clinical data remains insufficient to support the approval of its investigational skin cancer treatment. This reiteration signals a persistent regulatory hurdle for the company's lead candidate, casting doubt on the near-term viability of its market entry.